Investors Encouraged to Seek Compensation over Alleged Misconduct
Bronstein Gewirtz Grossman LLC Investigates Potential Claims Against PepGen Inc.
Attorney Advertising--Bronstein Gewirtz Grossman LLC is investigating potential claims on behalf of purchasers of PepGen Inc.
Bronstein Gewirtz Grossman LLC, a nationally recognized law firm with a history of representing investors in securities fraud class actions, is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PGEN) securities.
On December 4, 2023, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to PepGen in connection with the Company's Biologics License Application ("BLA") for its investigational drug, pegbelfermin. The CRL stated that the FDA had identified deficiencies related to the design and conduct of PepGen's clinical trials, as well as issues with the Company's manufacturing process. As a result, the FDA declined to approve PepGen's BLA.
Following this news, PepGen's stock price fell significantly. Shareholders have now filed a class action lawsuit against the Company, alleging that it made false and misleading statements about the prospects for its drug development program and the regulatory approval process.
Bronstein Gewirtz Grossman LLC is investigating the potential claims of PepGen investors. The firm is committed to advocating for the rights of shareholders who have been wronged by corporate misconduct. If you purchased PepGen securities and have suffered losses, you are encouraged to contact Bronstein Gewirtz Grossman LLC for a free and confidential consultation.
Comments